DOYLESTOWN, PA. - May 1, 2007 - The Quigley Corporation (Nasdaq: QGLY)
today announced it has retained CRT Capital Group LLC as its financial advisor
and investment banker.
CRT will provide Quigley with financial advisory services and assist the
Company in developing and evaluating strategic and capital market alternatives
in the ordinary course of its ongoing business planning. In addition, CRT will
serve as a market maker in Quigley's common stock.
Guy J. Quigley, Chairman, President and Chief Executive Officer, said, "We
are very pleased to have a high-caliber firm like CRT come on board. We believe
an experienced financial advisor and investment banker will benefit, as well as
complement, our internal efforts to enhance long-term shareholder value."
About CRT Capital Group LLC
CRT Capital Group LLC, www.crtllc.com,
is a full-service investment banking and
institutional securities firm that provides capital markets, research and
advisory services to its corporate and institutional clients. Based in
Stamford, Connecticut, CRT's more than 90 professionals have significant
experience assisting middle-market companies and their investors with a wide
range of financial services and products in both public and private capital
markets.
About The Quigley Corporation
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a
diversified natural health medical science company. Its Cold Remedy segment is
a leading marketer and manufacturer of the COLD-EEZE® family of lozenges,
gums and sugar free tablets clinically proven to cut the common cold nearly in
half. COLD-EEZE customers include leading national wholesalers and
distributors, as well as independent and chain food, drug and mass merchandise
stores and pharmacies. The Quigley Corporation has several wholly owned
subsidiaries. Darius International markets health and wellness products through
its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc.
consists of two FDA approved facilities to manufacture COLD- EEZE® lozenges
as well as fulfill other contract manufacturing opportunities. Quigley Pharma
Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and
commercialize a pipeline of patented botanical and naturally derived
prescription drugs.
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements" within the meaning of the Private Securities Litigation Reform
Act of 1995 and involve known and unknown risk, uncertainties and other factors
that may cause the Company's actual performance or achievements to be
materially different from the results, performance or achievements expressed or
implied by the forward-looking statement. Factors that impact such
forward-looking statements include, among others, changes in worldwide general
economic conditions, changes in interest rates, government regulations, and
worldwide competition.
